الفهرس | Only 14 pages are availabe for public view |
Abstract Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent a recent class of oral hypoglycemic agents available to treat patients with type 2 diabetes mellitus in addition, SGLT2i have been shown to reduce cardiovascular death risk and HF worsening in patients with HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), regardless of diabetes status. A post-infectious complication of rheumatic fever, rheumatic valvular heart disease caused by an atypical immunological response to streptococcal pharyngitis, which in turn causes valvular damage that is considered a major cardiac condition in many underdeveloped nations, including Egypt, and mitral regurgitation (MR) is considered as a common valve lesion. We enrolled 150 patients with severe rheumatic mitral regurgitation and preserved LV function (LV EF > 60%) in A prospective cohort study; half of them received Dapagliflozin and the others did not to assess the effect of dapagliflozin in patients with severe mitral regurgitation and preserved LV function The main findings is there were significant improvement in patients who received dapagliflozin (cases) compared to those who did not (control) with median score of KCCQ for cases was (71.5) compared to (62.6) for control group, p value < 0.001 ) with no statistically significant difference between the two groups regarding basal GLS and GLS after 3 months of follow up. |